

Press Release



Notice of the Establishment of ASKA Pharmaceutical Holdings Co., Ltd.

TOKYO, April 1st, 2021 - ASKA Pharmaceutical Holdings Co., Ltd. (Headquarters: Minato-ku, Tokyo, President: Takashi Yamaguchi, hereinafter “ASKA”) announced that ASKA was established as the wholly-owned parent company of ASKA Pharmaceutical Co., Ltd. and listed on the First Section of the Tokyo Stock Exchange today through a sole-share transfer.

Company Overview

Company Name	ASKA Pharmaceutical Holdings Co., Ltd.
Established	April 1, 2021
Head Office	5-1, Shibaura 2-chome, Minato-ku, Tokyo
Description of Business	Business management of subsidiaries, etc. that engage in manufacturing, sale, import/export, clinical examinations and testing operations of pharmaceuticals, quasi-drugs, foods, veterinary drugs, feeds and feed additives and medical devices, etc. and related operations
Representative	Takashi Yamaguchi President, Representative Director
Capital	1,197million yen
Number of Issued Shares	30,563,199 shares
End of Fiscal Year	March 31
Accounting Auditor	Seiyo Audit Corporation
Administrator of Shareholder Registry	Mitsubishi UFJ Trust and Banking Corporation
Listed Stock Exchanges	First Section, Tokyo Stock Exchange
Trading Unit	100 shares
URL	https://www.aska-pharma-hd.co.jp/english/

【Contact】

Corporate Planning Department, ASKA Pharmaceutical Holdings Co., Ltd.
TEL: +81-3-5484-8366